Cargando…
Predictive biological factors for late survival in patients with HER2-positive breast cancer
The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors for late...
Autores principales: | Kang, Young-Joon, Oh, Se Jeong, Bae, Soo Youn, Kim, Eun-Kyu, Lee, Young-Jin, Park, Eun Hwa, Jeong, Joon, Park, Heung Kyu, Suh, Young Jin, Kim, Yong-Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328940/ https://www.ncbi.nlm.nih.gov/pubmed/37420033 http://dx.doi.org/10.1038/s41598-023-38200-y |
Ejemplares similares
-
A Microbiota-Dependent Subset of Skin Macrophages Protects Against Cutaneous Bacterial Infection
por: Park, Young Joon, et al.
Publicado: (2022) -
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021) -
Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress
por: Park, Eun Hwa, et al.
Publicado: (2017) -
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
por: Kim, Yun Yeong, et al.
Publicado: (2018) -
OASL1 deficiency promotes antiviral protection against genital herpes simplex virus type 2 infection by enhancing type I interferon production
por: Oh, Ji Eun, et al.
Publicado: (2016)